Lexaria Provides Guidance on Upcoming R&D
KELOWNA, BC / ACCESSWIRE / February 1, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces applied R&D programs to begin immediately. Lexaria recently closed an more...
Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO(TM) Against Vascepa®
– LYPDISO ™ demonstrated a statistically significant 46% relative percent increase in EPA change from baseline over Vascepa ® – – LYPDISO ™ demonstrated a 39% relative difference in response over Vascepa in TG reduction more...
BIOLASE Urges Stockholders To Vote Today “FOR” The Reverse Stock Split
BIOLASE Urges Stockholders To Vote Today “FOR” The Reverse Stock Split The Adjourned BIOLASE Special Meeting Reconvenes Tuesday, February 16, 2021 PR Newswire FOOTHILL RANCH, Calif. , Feb. 1, 2021 /PRNewswire/ — BIOLASE, Inc. (NASDAQ: more...